Kukje Pharma Co., Ltd. (002720.KS)
KRW 4970.0
(-2.17%)
KRW 4970.0
(-2.17%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 20.07 Billion KRW | -12.95% |
| 2022 | 23.05 Billion KRW | -18.01% |
| 2021 | 28.12 Billion KRW | -17.59% |
| 2020 | 34.12 Billion KRW | 21.23% |
| 2019 | 28.14 Billion KRW | 11.07% |
| 2018 | 25.34 Billion KRW | -20.74% |
| 2017 | 31.97 Billion KRW | 19.75% |
| 2016 | 26.7 Billion KRW | -33.04% |
| 2015 | 39.87 Billion KRW | 14.71% |
| 2014 | 34.76 Billion KRW | 2.53% |
| 2013 | 33.9 Billion KRW | 30.97% |
| 2012 | 25.88 Billion KRW | 3.8% |
| 2011 | 24.94 Billion KRW | -40.24% |
| 2010 | 41.73 Billion KRW | 12.31% |
| 2009 | 37.15 Billion KRW | 14.11% |
| 2008 | 32.56 Billion KRW | 147.73% |
| 2007 | 13.14 Billion KRW | -10.78% |
| 2006 | 14.73 Billion KRW | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 20.82 Billion KRW | 16.87% |
| 2024 Q1 | 17.81 Billion KRW | -11.22% |
| 2023 Q3 | 20.88 Billion KRW | 7.7% |
| 2023 Q4 | 20.07 Billion KRW | -3.91% |
| 2023 Q1 | 20.28 Billion KRW | -12.03% |
| 2023 Q2 | 19.39 Billion KRW | -4.36% |
| 2023 FY | 20.07 Billion KRW | -12.95% |
| 2022 Q1 | 24.4 Billion KRW | -13.2% |
| 2022 FY | 23.05 Billion KRW | -18.01% |
| 2022 Q4 | 23.05 Billion KRW | 9.21% |
| 2022 Q3 | 21.11 Billion KRW | 0.97% |
| 2022 Q2 | 20.9 Billion KRW | -14.33% |
| 2021 Q2 | 34.02 Billion KRW | 0.28% |
| 2021 Q1 | 33.93 Billion KRW | -0.57% |
| 2021 FY | 28.12 Billion KRW | -17.59% |
| 2021 Q4 | 28.12 Billion KRW | -9.17% |
| 2021 Q3 | 30.95 Billion KRW | -9.02% |
| 2020 Q1 | 22.89 Billion KRW | -18.67% |
| 2020 Q3 | 31.03 Billion KRW | 10.02% |
| 2020 Q4 | 34.12 Billion KRW | 9.95% |
| 2020 FY | 34.12 Billion KRW | 21.23% |
| 2020 Q2 | 28.2 Billion KRW | 23.22% |
| 2019 Q4 | 28.14 Billion KRW | -9.9% |
| 2019 FY | 28.14 Billion KRW | 11.07% |
| 2019 Q3 | 31.23 Billion KRW | -5.0% |
| 2019 Q2 | 32.88 Billion KRW | 3.42% |
| 2019 Q1 | 31.79 Billion KRW | 25.47% |
| 2018 Q4 | 25.34 Billion KRW | 8.16% |
| 2018 FY | 25.34 Billion KRW | -20.74% |
| 2018 Q1 | 29.64 Billion KRW | -7.3% |
| 2018 Q2 | 26.35 Billion KRW | -11.08% |
| 2018 Q3 | 23.42 Billion KRW | -11.1% |
| 2017 Q1 | 29.81 Billion KRW | 11.67% |
| 2017 FY | 31.97 Billion KRW | 19.75% |
| 2017 Q4 | 31.97 Billion KRW | 3.64% |
| 2017 Q3 | 30.85 Billion KRW | -0.68% |
| 2017 Q2 | 31.06 Billion KRW | 4.17% |
| 2016 Q3 | 28.17 Billion KRW | -13.51% |
| 2016 Q2 | 32.57 Billion KRW | -12.78% |
| 2016 Q1 | 37.35 Billion KRW | -6.33% |
| 2016 FY | 26.7 Billion KRW | -33.04% |
| 2016 Q4 | 26.7 Billion KRW | -5.24% |
| 2015 Q3 | 33.44 Billion KRW | -17.21% |
| 2015 Q2 | 40.39 Billion KRW | 2.49% |
| 2015 Q1 | 39.41 Billion KRW | 13.38% |
| 2015 FY | 39.87 Billion KRW | 14.71% |
| 2015 Q4 | 39.87 Billion KRW | 19.23% |
| 2014 Q3 | 32.79 Billion KRW | -3.42% |
| 2014 Q1 | 34.45 Billion KRW | 1.62% |
| 2014 Q4 | 34.76 Billion KRW | 6.01% |
| 2014 FY | 34.76 Billion KRW | 2.53% |
| 2014 Q2 | 33.95 Billion KRW | -1.46% |
| 2013 FY | 33.9 Billion KRW | 30.97% |
| 2013 Q2 | 26.23 Billion KRW | 10.43% |
| 2013 Q3 | 31.39 Billion KRW | 19.68% |
| 2013 Q4 | 33.9 Billion KRW | 7.98% |
| 2013 Q1 | 23.75 Billion KRW | -8.23% |
| 2012 Q1 | 19.85 Billion KRW | 0.0% |
| 2012 Q4 | 25.88 Billion KRW | 0.0% |
| 2012 FY | 25.88 Billion KRW | 3.8% |
| 2011 FY | 24.94 Billion KRW | -40.24% |
| 2011 Q1 | 41.73 Billion KRW | -6.84% |
| 2011 Q2 | 39.44 Billion KRW | -5.49% |
| 2011 Q3 | 32.54 Billion KRW | -17.48% |
| 2010 Q4 | 44.79 Billion KRW | -0.01% |
| 2010 FY | 41.73 Billion KRW | 12.31% |
| 2010 Q2 | 44.15 Billion KRW | 18.83% |
| 2010 Q3 | 44.8 Billion KRW | 1.46% |
| 2010 Q1 | 37.15 Billion KRW | -11.86% |
| 2009 FY | 37.15 Billion KRW | 14.11% |
| 2009 Q4 | 42.15 Billion KRW | 0.62% |
| 2009 Q3 | 41.89 Billion KRW | -1.42% |
| 2009 Q2 | 42.5 Billion KRW | 30.51% |
| 2009 Q1 | 32.56 Billion KRW | -7.42% |
| 2008 Q1 | 13.14 Billion KRW | -19.6% |
| 2008 Q2 | 19.26 Billion KRW | 46.52% |
| 2008 Q4 | 35.17 Billion KRW | 57.39% |
| 2008 Q3 | 22.34 Billion KRW | 16.03% |
| 2008 FY | 32.56 Billion KRW | 147.73% |
| 2007 Q2 | 17.01 Billion KRW | 0.0% |
| 2007 Q4 | 16.34 Billion KRW | 8.0% |
| 2007 FY | 13.14 Billion KRW | -10.78% |
| 2007 Q3 | 15.13 Billion KRW | -11.02% |
| 2006 FY | 14.73 Billion KRW | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -128.035% |
| Dong-A Socio Holdings Co., Ltd. | 572.02 Billion KRW | 96.491% |
| Ildong Holdings Co., Ltd. | 310.87 Billion KRW | 93.543% |
| HANDOK Inc. | 283.45 Billion KRW | 92.919% |
| Yuhan Corporation | -69.18 Billion KRW | 129.012% |
| Dong-A ST Co., Ltd. | 193.95 Billion KRW | 89.651% |
| SAMSUNG PHARM. Co., LTD. | -3.68 Billion KRW | 644.579% |
| Hanmi Pharm. Co., Ltd. | 517.88 Billion KRW | 96.124% |
| Hanall Biopharma Co.,Ltd | -32.43 Billion KRW | 161.89% |
| Ilyang Pharmaceutical Co.,Ltd | 75.67 Billion KRW | 73.476% |
| Dong Sung Bio Pharm.Co.,Ltd. | 36.83 Billion KRW | 45.511% |
| MYUNGMOON Pharm co.,Ltd | 82.52 Billion KRW | 75.676% |
| Hana Pharm Co., Ltd. | 25.1 Billion KRW | 20.058% |
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -128.035% |
| Ilsung Pharmaceuticals Co., Ltd. | -159.84 Billion KRW | 112.557% |
| REYON Pharmaceutical Co., Ltd. | 200.94 Billion KRW | 90.011% |
| Aprogen pharmaceuticals,Inc. | 170.94 Billion KRW | 88.258% |
| JW Holdings Corporation | 480.68 Billion KRW | 95.824% |
| Ildong Pharmaceutical Co., Ltd. | 164.58 Billion KRW | 87.804% |
| Chong Kun Dang Pharmaceutical Corp. | 117.53 Million KRW | -16978.133% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | 86.997% |
| Shin Poong Pharm.Co.,Ltd. | 2.35 Billion KRW | -753.656% |
| Hyundai Pharmaceutical Co., Ltd. | 23 Billion KRW | 12.735% |
| Samil Pharmaceutical Co.,Ltd | 174.97 Billion KRW | 88.528% |
| Jeil Pharmaceutical Co.,Ltd | 51.97 Billion KRW | 61.381% |
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -128.035% |
| Kwang Dong Pharmaceutical Co., Ltd. | 158.29 Billion KRW | 87.32% |
| Daewoong pharmaceutical Co.,Ltd | 358.17 Billion KRW | 94.396% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | 86.997% |
| Yuhan Corporation | -69.18 Billion KRW | 129.012% |
| Jeil Pharma Holdings Inc | 135.99 Billion KRW | 85.24% |
| Yungjin Pharm. Co., Ltd. | 59.67 Billion KRW | 66.364% |
| Suheung Co., Ltd. | 429.14 Billion KRW | 95.323% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | 86.997% |
| Samjin Pharmaceuticals Co., Ltd. | 116.23 Billion KRW | 82.732% |
| Korea United Pharm Inc. | 16.42 Billion KRW | -22.204% |
| CKD Bio Corp. | 143.29 Billion KRW | 85.993% |
| Daewon Pharmaceutical Co., Ltd. | 116.06 Billion KRW | 82.706% |
| Dongwha Pharm.Co.,Ltd | -24.06 Billion KRW | 183.42% |
| Whan In Pharm Co.,Ltd. | -44.73 Billion KRW | 144.87% |
| Shin Poong Pharm.Co.,Ltd. | 2.35 Billion KRW | -753.656% |
| Chong Kun Dang Holdings Corp. | 422.84 Billion KRW | 95.253% |
| Boryung Corporation | 187.72 Billion KRW | 89.308% |
| Bukwang Pharmaceutical Co., Ltd. | -71.84 Billion KRW | 127.94% |
| Ilyang Pharmaceutical Co.,Ltd | 75.67 Billion KRW | 73.476% |
| JW Lifescience Corporation | 26.09 Billion KRW | 23.068% |